Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. V. Raju, P. Jackson, C. Courville, C. McNicholas, P. A. Sloane, G. Sabbatinin, L. P. Tang, M. Mazur, J. P. Clancy, F. J. Accurso, J. E. Blalock, M. T. Dransfield, S. M. Rowe (Birmingham, Denver, Cincinnati, United States Of America). Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator (CFTR) ion transport. Eur Respir J 2013; 42: Suppl. 57, 2102

Member's Comments

No comment yet.

Related content which might interest you: Cystic fibrosis transmembrane conductance regulator pharmacotherapy Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=88 Year: 2006 Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis Source: Eur Respir Rev 2013; 22: 58-65 Year: 2013 Atypical cystic fibrosis Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=38 Year: 2006 LATE-BREAKING ABSTRACT: Reducing inflammation in the lung by targeting the endothelial cystic fibrosis transmembrane conductance regulator with copper-tobramycin Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014 A three miRNA signature regulates the CF transmembrane conductance regulator (CFTR) in cystic fibrosis airway epithelium Source: Annual Congress 2011 - Epithelial cells: role in health and disease Year: 2011 Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID) Source: Breathe, 17 (3) 210088; 10.1183/20734735.0088-2021 Year: 2021 The cystic fibrosis transmembrane conductance regulator: state of the art Source: Breathe 2008; 5: 163-167 Year: 2008 Oral contraceptives do not appear to affect cystic fibrosis disease severity Source: Eur Respir J 2013; 41: 67-73 Year: 2013 Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis Source: Annual Congress 2013 –Cystic fibrosis: lung function and change of lung function in infants and children before and after treatment Year: 2013 Channelopathies in bronchiectasis Source: Eur Respir Mon 2011; 52: 150-162 Year: 2011 The cystic fibrosis transmembrane conductance regulator and its modulators: clinical implications Source: Virtual Congress 2020 – Respiratory infections Year: 2020 Cystic fibrosis and survival to 40 years: a study of cystic fibrosis transmembrane conductance regulator function Source: Eur Respir J 2011; 37: 1076-1082 Year: 2011 Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient Source: Eur Respir J 2002; 19: 374-376 Year: 2002 CFTR: cystic fibrosis and beyond Source: Eur Respir J 2014; 44: 1042-1054 Year: 2014 Increased systemic inflammation in cystic fibrosis (CF) is associated with deterioration in lung clearance index (LCI) Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology Year: 2014 Cross-talk of inflammatory mediators and airway epithelium reveals the cystic fibrosis transmembrane conductance regulator as a major target Source: ERJ Open Res, 7 (4) 00247-2021; 10.1183/23120541.00247-2021 Year: 2021 Expression and function of cystic fibrosis transmembrane conductance regulator in rat intrapulmonary arteries Source: Eur Respir J 2007; 30: 857-864 Year: 2007 Cystic fibrosis: to ion transport and beyond Source: Eur Respir J 2010; 36: 991-992 Year: 2010 Deleterious impact of Pseudomonas aeruginosa on cystic fibrosis transmembrane conductance regulator function and rescue in airway epithelial cells Source: Eur Respir J 2015; 45: 1590-1602 Year: 2015